Valerie Harding-Start
Independent DirectorDr. Valerie Harding-Start, also known as Val, Ph.D., has been an Independent Director of Erasca, Inc. since June 2019. Since February 2019, Dr. Harding-Start has been a principal and advisor at Start Pharma Consulting LLC. From 2015 to January 2019, Dr. Harding-Start served as Ignyta, Inc.’s Senior Vice President of Chemistry, Manufacturing and Controls (CMC), as well as Site Head during Ignyta’s acquisition by Roche. Prior to Ignyta, Dr. Harding-Start served as Vice President of Product Differentiation, Pharmaceutical Sciences for Worldwide Research and Development at Pfizer, Inc. Dr. Harding-Start is also a member of the community of practice and thought partner for Smallify LLC, an innovation capacity-building firm. Dr. Harding-Start holds a B. Pharm. from the University of London and a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham.
Positions
- Company NameErasca, Inc.Stock CodeERASPositionIndependent DirectorColleagues
- JEJonathan E. LimCo-Founder, Chairman & CEO
- DMDavid M. ChackoCFO & Chief Business Officer
- MDMichael D. VarneyChairman of Research & Development, Scientific Advisory Board Member and Director
- SRShannon R. MorrisChief Medical Officer
- ATAlison Tjosvold MilhousSenior Vice President of Accounting
- JAJames A. BristolLead Independent Director
- AWAlexander Whitman CasdinIndependent Director
